Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures

Molecular Pharmaceutics

Volumn 8, Issue 4, 2011, Pages 1016-1024

  Wang, Yuwei ^a   Panasiuk, Alexandra ^b   Grainger, David W ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

alendronate; bone metabolism; farnesyl pyrophosphate synthase; mineralization; osteoblasts; osteoclasts; siRNA

Indexed keywords

ALENDRONIC ACID; GERANYLTRANSFERASE; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE METABOLISM; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DRUG TARGETING; MALE; MINERALIZATION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL;

ALENDRONATE; ALKALINE PHOSPHATASE; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; GERANYLTRANSTRANSFERASE; MALE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 79961098727     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100374n     Document Type: Article

References (58)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA, J. Am. Med. Assoc. 2001, 285 (6), 785 - 95.
2. Rogers, M. J.; Watts, D. J.; Russell, R. G. Overview of bisphosphonates Cancer 1997, 80 (8 Suppl.) 1652-60 (Pubitemid 27444037)
3. Marx, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J. Oral Maxillofacial Surg. 2003, 61 (9) 1115-7 (Pubitemid 37064711)
4. Dodson, T. B.; Guralnick, W. C.; Donoff, R. B.; Kaban, L. B. Massachusetts General Hospital/Harvard Medical School MD oral and maxillofacial surgery program: a 30-year review J. Oral Maxillofacial Surg. 2004, 62 (1) 62-5 (Pubitemid 38056132)
5. Ruggiero, S. L.; Mehrotra, B.; Rosenberg, T. J.; Engroff, S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J. Oral Maxillofacial Surg. 2004, 62 (5) 527-34 (Pubitemid 38542516)
6. Khan, S. A.; Kanis, J. A.; Vasikaran, S.; Kline, W. F.; Matuszewski, B. K.; McCloskey, E. V.; Beneton, M. N.; Gertz, B. J.; Sciberras, D. G.; Holland, S. D.; Orgee, J.; Coombes, G. M.; Rogers, S. R.; Porras, A. G. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis J Bone Miner. Res. 1997, 12 (10) 1700-7 (Pubitemid 27422371)
7. Yang, K. H.; Won, J. H.; Yoon, H. K.; Ryu, J. H.; Choo, K. S.; Kim, J. S. High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model Yonsei Med. J. 2007, 48 (4) 653-8 (Pubitemid 47496728)
8. Sebba, A. Osteoporosis: how long should we treat? Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15 (6) 502-7
9. Sellmeyer, D. E. Atypical fractures as a potential complication of long-term bisphosphonate therapy JAMA, J. Am. Med. Assoc. 2010, 304 (13) 1480-4
10. Odvina, C. V.; Zerwekh, J. E.; Rao, D. S.; Maalouf, N.; Gottschalk, F. A.; Pak, C. Y. Severely suppressed bone turnover: a potential complication of alendronate therapy J. Clin. Endocrinol. Metab. 2005, 90 (3) 1294-301 (Pubitemid 40463979)
11. van Beek, E.; Pieterman, E.; Cohen, L.; Lowik, C.; Papapoulos, S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem. Biophys. Res. Commun. 1999, 264 (1) 108-11 (Pubitemid 29500472)
12. Bergstrom, J. D.; Bostedor, R. G.; Masarachia, P. J.; Reszka, A. A.; Rodan, G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase Arch. Biochem. Biophys. 2000, 373 (1) 231-41 (Pubitemid 30046509)
13. Kavanagh, K. L.; Guo, K.; Dunford, J. E.; Wu, X.; Knapp, S.; Ebetino, F. H.; Rogers, M. J.; Russell, R. G.; Oppermann, U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (20) 7829-34
14. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J. Pharmacol. Exp. Ther. 2001, 296 (2) 235-42 (Pubitemid 32112446)
15. Rondeau, J. M.; Bitsch, F.; Bourgier, E.; Geiser, M.; Hemmig, R.; Kroemer, M.; Lehmann, S.; Ramage, P.; Rieffel, S.; Strauss, A.; Green, J. R.; Jahnke, W. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs ChemMedChem 2006, 1 (2) 267-73 (Pubitemid 43700307)
16. Lacal, J. C. Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling FEBS Lett. 1997, 410 (1) 73-7 (Pubitemid 27283387)
17. Constantz, B. R.; Ison, I. C.; Fulmer, M. T.; Poser, R. D.; Smith, S. T.; VanWagoner, M.; Ross, J.; Goldstein, S. A.; Jupiter, J. B.; Rosenthal, D. I. Skeletal repair by in situ formation of the mineral phase of bone Science 1995, 267 (5205) 1796-9
18. Rogers, M. J. New insights into the molecular mechanisms of action of bisphosphonates Curr. Pharm. Des. 2003, 9 (32) 2643-58 (Pubitemid 37456015)
19. Tenenbaum, H. C.; Shelemay, A.; Girard, B.; Zohar, R.; Fritz, P. C. Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses J. Periodontol. 2002, 73 (7) 813-22
20. Reinholz, G. G.; Getz, B.; Sanders, E. S.; Karpeisky, M. Y.; Padyukova, N.; Mikhailov, S. N.; Ingle, J. N.; Spelsberg, T. C. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue Breast Cancer Res. Treat. 2002, 71 (3) 257-68 (Pubitemid 34263989)
21. Hammond, S. M.; Bernstein, E.; Beach, D.; Hannon, G. J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells Nature 2000, 404 (6775) 293-6 (Pubitemid 30163547)
22. Calle, Y.; Jones, G. E.; Jagger, C.; Fuller, K.; Blundell, M. P.; Chow, J.; Chambers, T.; Thrasher, A. J. WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption Blood 2004, 103 (9) 3552-61 (Pubitemid 38525693)
23. Aigner, A. Delivery systems for the direct aplication of siRNAs to induce RNA interference (RNAi) in vivo J. Biomed. Biotechnol. 2006, 2006, 1-15
24. de Fougerolles, A.; Vornlocher, H. P.; Maraganore, J.; Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics Nat. Rev. Drug Discovery 2007, 6 (6) 443-53 (Pubitemid 47064567)
25. Wang, Y.; Lebowitz, D.; Sun, C.; Thang, H.; Grynpas, M. D.; Glogauer, M. Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis J. Bone Miner. Res. 2008, 23 (2) 260-70 (Pubitemid 351160040)
26. Takami, M.; Kim, N.; Rho, J.; Choi, Y. Stimulation by toll-like receptors inhibits osteoclast differentiation J. Immunol. 2002, 169 (3) 1516-23 (Pubitemid 34809198)
27. Issack, P. S.; Lauerman, M. H.; Helfet, D. L.; Doty, S. B.; Lane, J. M. Alendronate Inhibits PTH (1-34)-induced Bone Morphogenetic Protein Expression in MC3T3-E1 Preosteoblastic Cells HSS J. 2007, 3 (2) 169-72
28. Chamberlain, L. M.; Godek, M. L.; Gonzalez-Juarrero, M.; Grainger, D. W. Phenotypic non-equivalence of murine (monocyte-) macrophage cells in biomaterial and inflammatory models J. Biomed. Mater. Res. A 2009, 88 (4) 858-71
29. Trebec, D. P.; Chandra, D.; Gramoun, A.; Li, K.; Heersche, J. N.; Manolson, M. F. Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases J. Cell. Biochem. 2007, 101 (1) 205-20 (Pubitemid 46652585)
30. Lee, Y. K.; Song, J.; Lee, S. B.; Kim, K. M.; Choi, S. H.; Kim, C. K.; LeGeros, R. Z.; Kim, K. N. Proliferation, differentiation, and calcification of preosteoblast-like MC3T3-E1 cells cultured onto noncrystalline calcium phosphate glass J. Biomed. Mater. Res. A 2004, 69 (1) 188-95 (Pubitemid 38364976)
31. Lambrinoudaki, I.; Christodoulakos, G.; Botsis, D. Bisphosphonates Ann. N.Y. Acad. Sci. 2006, 1092, 397-402 (Pubitemid 47092356)
32. Hausler, K. D.; Horwood, N. J.; Chuman, Y.; Fisher, J. L.; Ellis, J.; Martin, T. J.; Rubin, J. S.; Gillespie, M. T. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation J. Bone Miner. Res. 2004, 19 (11) 1873-81 (Pubitemid 41103439)
33. Wang, Y.; Grainger, D. W. siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption Pharm. Res. 2010, 27 (7) 1273-84
34. Naidu, A.; Dechow, P. C.; Spears, R.; Wright, J. M.; Kessler, H. P.; Opperman, L. A. The effects of bisphosphonates on osteoblasts in vitro Oral Surg., Oral. Med., Oral. Pathol., Oral. Radiol., Endod. 2008, 106 (1) 5-13
35. Sato, M.; Grasser, W.; Endo, N.; Akins, R.; Simmons, H.; Thompson, D. D.; Golub, E.; Rodan, G. A. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J. Clin. Invest. 1991, 88 (6) 2095-105
36. Kim, H. K.; Kim, J. H.; Abbas, A. A.; Yoon, T. R. Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study Clin. Orthop. Relat. Res. 2009, 467 (12) 3121-8
37. Reinholz, G. G.; Getz, B.; Pederson, L.; Sanders, E. S.; Subramaniam, M.; Ingle, J. N.; Spelsberg, T. C. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts Cancer Res. 2000, 60 (21) 6001-7
38. Im, G. I.; Qureshi, S. A.; Kenney, J.; Rubash, H. E.; Shanbhag, A. S. Osteoblast proliferation and maturation by bisphosphonates Biomaterials 2004, 25 (18) 4105-15 (Pubitemid 38388576)
39. Sahni, M.; Guenther, H. L.; Fleisch, H.; Collin, P.; Martin, T. J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts J. Clin. Invest. 1993, 91 (5) 2004-11 (Pubitemid 23141472)
40. Hughes, D. E.; MacDonald, B. R.; Russell, R. G.; Gowen, M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow J. Clin. Invest. 1989, 83 (6) 1930-5 (Pubitemid 19148862)
41. Cecchini, M. G.; Felix, R.; Fleisch, H.; Cooper, P. H. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages J. Bone Miner. Res. 1987, 2 (2) 135-42
42. Lowik, C. W.; van der Pluijm, G.; van der Wee-Pals, L. J.; van Treslong-De Groot, H. B.; Bijvoet, O. L. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate J. Bone Miner. Res. 1988, 3 (2) 185-92
43. Hughes, D. E.; Wright, K. R.; Uy, H. L.; Sasaki, A.; Yoneda, T.; Roodman, G. D.; Mundy, G. R.; Boyce, B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo J. Bone Miner. Res. 1995, 10 (10) 1478-87
44. Ito, M.; Amizuka, N.; Nakajima, T.; Ozawa, H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment Bone 1999, 25 (4) 447-52 (Pubitemid 29424238)
45. Fisher, J. E.; Rogers, M. J.; Halasy, J. M.; Luckman, S. P.; Hughes, D. E.; Masarachia, P. J.; Wesolowski, G.; Russell, R. G.; Rodan, G. A.; Reszka, A. A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (1) 133-8 (Pubitemid 29036065)
46. Shipman, C. M.; Croucher, P. I.; Russell, R. G.; Helfrich, M. H.; Rogers, M. J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res. 1998, 58 (23) 5294-7 (Pubitemid 28551102)
47. Luckman, S. P.; Hughes, D. E.; Coxon, F. P.; Graham, R.; Russell, G.; Rogers, M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J. Bone Miner. Res. 1998, 13 (4) 581-9 (Pubitemid 28163009)
48. Nishikawa, M.; Akatsu, T.; Katayama, Y.; Yasutomo, Y.; Kado, S.; Kugal, N.; Yamamoto, M.; Nagata, N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures Bone 1996, 18 (1) 9-14 (Pubitemid 26047526)
49. Giuliani, N.; Pedrazzoni, M.; Negri, G.; Passeri, G.; Impicciatore, M. Girasole, G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo Bone 1998, 22 (5) 455-61
50. Garcia-Moreno, C.; Serrano, S.; Nacher, M.; Farre, M.; Diez, A.; Marinoso, M. L.; Carbonell, J.; Mellibovsky, L.; Nogues, X.; Ballester, J.; Aubia, J. Effect of alendronate on cultured normal human osteoblasts Bone 1998, 22 (3) 233-9 (Pubitemid 28127478)
51. Reszka, A. A.; Halasy-Nagy, J. M.; Masarachia, P. J.; Rodan, G. A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase J. Biol. Chem. 1999, 274 (49) 34967-73 (Pubitemid 129509546)
52. Khokher, M. A.; Dandona, P. Diphosphonates inhibit human osteoblast secretion and proliferation Metabolism 1989, 38 (2) 184-7 (Pubitemid 19037686)
53. Klein, B. Y.; Ben-Bassat, H.; Breuer, E.; Solomon, V.; Golomb, G. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors J. Cell. Biochem. 1998, 68 (2) 186-94 (Pubitemid 28028076)
54. Plotkin, L. I.; Weinstein, R. S.; Parfitt, A. M.; Roberson, P. K.; Manolagas, S. C.; Bellido, T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin J. Clin. Invest. 1999, 104 (10) 1363-74
55. Giuliani, N.; Pedrazzoni, M.; Passeri, G.; Girasole, G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells Scand. J. Rheumatol. 1998, 27 (1) 38-41 (Pubitemid 28116468)
56. Vitte, C.; Fleisch, H.; Guenther, H. L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption Endocrinology 1996, 137 (6) 2324-33
57. Pan, B.; Farrugia, A. N.; To, L. B.; Findlay, D. M.; Green, J.; Lynch, K.; Zannettino, A. C. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE) J. Bone Miner. Res. 2004, 19 (1) 147-54 (Pubitemid 41295147)
58. Viereck, V.; Emons, G.; Lauck, V.; Frosch, K. H.; Blaschke, S.; Grundker, C.; Hofbauer, L. C. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts Biochem. Biophys. Res. Commun. 2002, 291 (3) 680-6 (Pubitemid 34687400)